Dr. Deniz Tschammler
Deniz Tschammler advises at the pulse of the global health markets. His clients include pharmaceutical and medical technology companies, providers of digital health solutions and their investors. Deniz assists organizations on transactions and collaborations, on market entry and access, on digitization strategies, in disputes with competitors and authorities as well as industry-specific compliance matters. He regularly advises on cross-border projects, including foreign trade law and investment control.
Foreign Direct Investment Control in Germany | Recent Facts and Figures
By Dr. Laura Stammwitz, Alexandra Heberle and Dr. Deniz Tschammler on Apr 29, 2024
Posted In Foreign Investment
Under the German Foreign Investment Control regime, the Government may review foreign investments in domestic target companies above certain thresholds. The Government has only recently published interesting statistics about the development of German investment screening over the past three years (available in German only). These statistics show that foreign investments across all industries have come...
Continue Reading
Conflict of Interest in Drug’s Evaluation by the European Medicines Agency
By Sabine Naugès and Dr. Deniz Tschammler on Apr 4, 2024
Posted In Compliance
In a judgment dated March 12, 2024, the Court of Justice of the European Union (the “Court of Justice“) was asked to clarify the scope of the principles that must be respected in the procedure conducted by the European Medicines Agency (EMA) for the evaluation of medicinal products. Background The appeal to the Court of...
Continue Reading
Foreign Investment Control in Germany | New Administrative Fees Regime
By Dr. Deniz Tschammler, Alexandra Heberle and Dr. Laura Stammwitz on Mar 25, 2024
Posted In Foreign Investment
Since January 1, 2024, the German Government now charges administrative fees for foreign invest-ment control (FIC) proceedings. Under the German FIC regime, the competent federal ministry, the Bundesministerium für Wirtschaft und Klimaschutz (BMWK), may review foreign investments in domestic target companies above certain thresholds. Based on a filing submitted by the direct acquirer, BMWK has...
Continue Reading
